203 related articles for article (PubMed ID: 34378195)
41. Genetic profiling of
Ennishi D; Mottok A; Ben-Neriah S; Shulha HP; Farinha P; Chan FC; Meissner B; Boyle M; Hother C; Kridel R; Lai D; Saberi S; Bashashati A; Shah SP; Morin RD; Marra MA; Savage KJ; Sehn LH; Steidl C; Connors JM; Gascoyne RD; Scott DW
Blood; 2017 May; 129(20):2760-2770. PubMed ID: 28351934
[TBL] [Abstract][Full Text] [Related]
42. Genomic profiling using array comparative genomic hybridization define distinct subtypes of diffuse large B-cell lymphoma: a review of the literature.
Tirado CA; Chen W; García R; Kohlman KA; Rao N
J Hematol Oncol; 2012 Sep; 5():54. PubMed ID: 22967872
[TBL] [Abstract][Full Text] [Related]
43. Aggressive B-cell lymphomas: frequency, immunophenotype, and genetics in a reference laboratory population.
Naeini YB; Wu A; O'Malley DP
Ann Diagn Pathol; 2016 Dec; 25():7-14. PubMed ID: 27806850
[TBL] [Abstract][Full Text] [Related]
44. Immunophenotypic and genetic characteristics of diffuse large B-cell lymphoma in Taiwan.
Chang ST; Chen SW; Ho CH; Kuo CC; Sakata S; Takeuchi K; Chuang SS
J Formos Med Assoc; 2016 Nov; 115(11):961-967. PubMed ID: 27773559
[TBL] [Abstract][Full Text] [Related]
45. High prevalence of the MYD88 mutation in testicular lymphoma: Immunohistochemical and genetic analyses.
Oishi N; Kondo T; Nakazawa T; Mochizuki K; Tanioka F; Oyama T; Yamamoto T; Iizuka J; Tanabe K; Shibata N; Kirito K; Katoh R
Pathol Int; 2015 Oct; 65(10):528-35. PubMed ID: 26388135
[TBL] [Abstract][Full Text] [Related]
46. Molecular subtyping of CD5+ diffuse large B-cell lymphoma based on DNA-targeted sequencing and Lymph2Cx.
Ma D; Ma Y; Ma Y; Liu J; Gu Y; Liu N; Xiang C; Liu H; Sang W
Front Oncol; 2022; 12():941347. PubMed ID: 36081566
[TBL] [Abstract][Full Text] [Related]
47. Prevalence and clinicopathologic features of CD30-positive de novo diffuse large B-cell lymphoma in Chinese patients: a retrospective study of 232 cases.
Gong QX; Lu TX; Liu C; Wang Z; Liang JH; Xu W; Li JY; Zhang ZH; Chen Q
Int J Clin Exp Pathol; 2015; 8(12):15825-35. PubMed ID: 26884853
[TBL] [Abstract][Full Text] [Related]
48. Differences in the cytogenetic alteration profiles of diffuse large B-cell lymphoma among Chinese and American patients.
Chen Y; Dave BJ; Zhu X; Chan WC; Iqbal J; Sanger WG; Fu K
Cancer Genet; 2013 May; 206(5):183-90. PubMed ID: 23849050
[TBL] [Abstract][Full Text] [Related]
49.
Tourneret A; Alame M; Rigau V; Bauchet L; Fabbro M; De Oliveira L; Cacheux V; Costes V; Lacheretz-Szablewski V
J Clin Pathol; 2021 Oct; 74(10):650-656. PubMed ID: 32912960
[TBL] [Abstract][Full Text] [Related]
50. Diffuse large B-cell lymphoma patient-derived xenograft models capture the molecular and biological heterogeneity of the disease.
Chapuy B; Cheng H; Watahiki A; Ducar MD; Tan Y; Chen L; Roemer MG; Ouyang J; Christie AL; Zhang L; Gusenleitner D; Abo RP; Farinha P; von Bonin F; Thorner AR; Sun HH; Gascoyne RD; Pinkus GS; van Hummelen P; Wulf GG; Aster JC; Weinstock DM; Monti S; Rodig SJ; Wang Y; Shipp MA
Blood; 2016 May; 127(18):2203-13. PubMed ID: 26773040
[TBL] [Abstract][Full Text] [Related]
51. Targetable activating mutations are very frequent in GCB and ABC diffuse large B-cell lymphoma.
Bohers E; Mareschal S; Bouzelfen A; Marchand V; Ruminy P; Maingonnat C; Ménard AL; Etancelin P; Bertrand P; Dubois S; Alcantara M; Bastard C; Tilly H; Jardin F
Genes Chromosomes Cancer; 2014 Feb; 53(2):144-53. PubMed ID: 24327543
[TBL] [Abstract][Full Text] [Related]
52. Mutations or copy number losses of CD58 and TP53 genes in diffuse large B cell lymphoma are independent unfavorable prognostic factors.
Cao Y; Zhu T; Zhang P; Xiao M; Yi S; Yang Y; Li Q; Ling S; Wang Y; Gao L; Zhu L; Wang J; Wang N; Huang L; Zhang P; Zhai Q; Qiu L; Zhou J
Oncotarget; 2016 Dec; 7(50):83294-83307. PubMed ID: 27825110
[TBL] [Abstract][Full Text] [Related]
53. Mutational landscape of B-cell post-transplant lymphoproliferative disorders.
Menter T; Juskevicius D; Alikian M; Steiger J; Dirnhofer S; Tzankov A; Naresh KN
Br J Haematol; 2017 Jul; 178(1):48-56. PubMed ID: 28419429
[TBL] [Abstract][Full Text] [Related]
54. Patients with double/triple copy number gains on C-MYC, BCL2, and/or BCL6 treated with standard chemotherapy have a similarly poor prognosis than those with high-grade B cell lymphoma with C-MYC and BCL2 and/or BCL6 rearrangements: a single-center experience on a consecutive cohort of large B cell lymphomas.
Willenbacher E; Willenbacher W; Weger R; Dominik W; Manzl C; Brunner A
Ann Hematol; 2020 Sep; 99(9):2125-2132. PubMed ID: 32613279
[TBL] [Abstract][Full Text] [Related]
55. MYC translocation and/or BCL 2 protein expression are associated with poor prognosis in diffuse large B-cell lymphoma.
Kawamoto K; Miyoshi H; Yoshida N; Nakamura N; Ohshima K; Sone H; Takizawa J
Cancer Sci; 2016 Jun; 107(6):853-61. PubMed ID: 27027803
[TBL] [Abstract][Full Text] [Related]
56. BCL2 Expression in First-Line Diffuse Large B-Cell Lymphoma Identifies a Patient Population With Poor Prognosis.
Punnoose E; Peale FV; Szafer-Glusman E; Lei G; Bourgon R; Do AD; Kim E; Zhang L; Farinha P; Gascoyne RD; Munoz FJ; Martelli M; Mottok A; Salles GA; Sehn LH; Seymour JF; Trnĕný M; Oestergaard MZ; Mundt KE; Vitolo U
Clin Lymphoma Myeloma Leuk; 2021 Apr; 21(4):267-278.e10. PubMed ID: 33303421
[TBL] [Abstract][Full Text] [Related]
57. Determination of the molecular subtypes of diffuse large B-cell lymphomas using immunohistochemistry: a case series from the Inselspital, Bern, and a critical appraisal of this determination in Switzerland.
Reber R; Banz Y; Garamvölgyi E; Perren A; Novak U
Swiss Med Wkly; 2013; 143():w13748. PubMed ID: 23740154
[TBL] [Abstract][Full Text] [Related]
58. SOCS1 mutation subtypes predict divergent outcomes in diffuse large B-Cell lymphoma (DLBCL) patients.
Schif B; Lennerz JK; Kohler CW; Bentink S; Kreuz M; Melzner I; Ritz O; Trümper L; Loeffler M; Spang R; Möller P
Oncotarget; 2013 Jan; 4(1):35-47. PubMed ID: 23296022
[TBL] [Abstract][Full Text] [Related]
59. Molecular Subtyping of Diffuse Large B-Cell Lymphoma Using a Novel Quantitative RT-PCR Assay.
Ta R; Santini C; Gou P; Lee G; Tai YC; O'Brien C; Fontecha M; Grant C; Bacon L; Finn S; Vandenberghe E; Quinn F; Dua R; Flavin R
J Mol Diagn; 2021 Mar; 23(3):323-340. PubMed ID: 33385586
[TBL] [Abstract][Full Text] [Related]
60. Immunohistochemical and molecular characteristics with prognostic significance in diffuse large B-cell lymphoma.
Bellas C; García D; Vicente Y; Kilany L; Abraira V; Navarro B; Provencio M; Martín P
PLoS One; 2014; 9(6):e98169. PubMed ID: 24887414
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]